to receive febuxostat (versus placebo) were less likely to experience a subsequent flare (30% versus 41%; P < 0.05) Specific characteristics for patients with infrequent flares (e.g., SU concentration >9 mg/dl, CKD, CVD) that might influence the risk-benefit assessment were considered, but due to insufficient data for these subgroups, the Voting Panel did not find that these conditions warranted stronger ULT recommendations specific to these subgroups. Initiating ULT is conditionally